Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study

Key Points

• This research aims to compare the efficacy and safety of the biosimilar BAT2506 to the reference drug golimumab in treating active psoriatic arthritis.
• Phase 3, multicenter, double-blind, randomized, parallel-group study with patients diagnosed with active psoriatic arthritis.
• Patients received either BAT2506 or golimumab over a 24-week period.
• Study registered under NCT05046431.
• BAT2506 demonstrated comparable efficacy to golimumab, with significant improvements in disease activity measures.
• Safety profiles were similar between BAT2506 and golimumab, with no unexpected adverse events reported.
• Detailed statistical outcomes are pending further analysis.